Abstract
In this issue of Blood, Usmani et al provide important information on second primary malignancies in patients treated with thalidomide and lenalidomide in the Arkansas total therapy trials.
Original language | English (US) |
---|---|
Pages (from-to) | 1537-1539 |
Number of pages | 3 |
Journal | Blood |
Volume | 120 |
Issue number | 8 |
DOIs |
|
State | Published - Aug 23 2012 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology